Posted by Michael Wonder on 20 Jan 2017
Allergan announces FDA approval of Rhofade (oxymetazoline hydrochloride) 1% cream for the topical treatment of persistent facial erythema associated with rosacea in adults
19 January 2017 - Once daily treatment reduces persistent facial erythema associated with rosacea through 12 hours.
Allergan announced today the approval of Rhofade cream by the U.S. FDA for the topical treatment of persistent facial erythema associated with rosacea in adults. Approval was based on two clinical studies that evaluated the primary efficacy endpoint on day 29.
